Characteristics of Binding of [3H]NE-100, a Novel Sigma-receptor Ligand, to Guinea-pig Brain Membranes
Overview
Authors
Affiliations
We examined the characteristics of binding of radiolabeled N,N-dipropyl-2-[4-methoxy-3-(2-phenyl-ethoxy)phenyl]- ethylamine monohydrochloride ([3H] NE-100), a highly potent and selective sigma-receptor ligand, to guinea-pig brain membranes. [3H]NE-100 showed saturable and reversible binding to sigma binding sites. A dissociation constant (Kd) and maximal numbers of binding sites (Bmax) obtained from Scatchard plot analysis were 1.2 +/- 0.1 nM and 1049.3 +/- 115.1 fmol/mg protein (n = 3), respectively. NE-100 was the most potent inhibitor of [3H]NE-100 binding among several structurally dissimilar sigma-receptor ligands, including haloperidol and (+)-pentazocine. (+)-Benzomorphanes had more than a 10-fold potent inhibitory activity over (-)-benzomorphanes, with regard to [3H]NE-100 binding. The binding of [3H]NE-100 was not influenced by histaminergic, dopaminergic, adrenergic, serotonergic cholinergic or glutaminergic agents at 10(-7) M. GTP-gamma-S and phenytoin also did not affect the binding of [3H]NE-100. A higher [3H]NE-100 binding was observed in the cerebellum and medulla oblongata. Except for the nuclear fraction, the highest level of [3H]NE-100 binding to subcellular fractions was observed in microsomal fractions. These results suggest that NE-100 selectively binds, with a high affinity, to sigma-1 binding sites in guinea-pig brain membranes, as an "antagonist".
Sigma non-opioid receptor 1 is a potential therapeutic target for long QT syndrome.
Song L, Bekdash R, Morikawa K, Quejada J, Klein A, Aina-Badejo D Nat Cardiovasc Res. 2022; 1(2):142-156.
PMID: 36051854 PMC: 9431959. DOI: 10.1038/s44161-021-00016-2.
Sigmar1's Molecular, Cellular, and Biological Functions in Regulating Cellular Pathophysiology.
Aishwarya R, Abdullah C, Morshed M, Remex N, Bhuiyan M Front Physiol. 2021; 12:705575.
PMID: 34305655 PMC: 8293995. DOI: 10.3389/fphys.2021.705575.
Oyer H, Sanders C, Kim F Front Pharmacol. 2019; 10:1141.
PMID: 31695608 PMC: 6816035. DOI: 10.3389/fphar.2019.01141.
Sabino V, Cottone P, Zhao Y, Steardo L, Koob G, Zorrilla E Psychopharmacology (Berl). 2009; 205(2):327-35.
PMID: 19440699 PMC: 2748837. DOI: 10.1007/s00213-009-1548-x.
Colabufo N, Berardi F, Contino M, Niso M, Abate C, Perrone R Naunyn Schmiedebergs Arch Pharmacol. 2004; 370(2):106-13.
PMID: 15322732 DOI: 10.1007/s00210-004-0961-2.